GATA4 and heart failure: This study suggests that sarpogrelate suppresses cardiomyocyte hypertrophy by inhibiting the ERK1/2–GATA4 signaling pathway, and that, in a mouse model of heart failure, sarpogrelate prevents the development of heart failure in both a 5-HT2A receptor-dependent and independent manner.